<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04201275</url>
  </required_header>
  <id_info>
    <org_study_id>HEC74647-P-02</org_study_id>
    <nct_id>NCT04201275</nct_id>
  </id_info>
  <brief_title>The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects</brief_title>
  <official_title>A Single-center, Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Consecutive Dose Study to Assess the Tolerability, Pharmacokinetics and Pharmacodynamics of HEC74647 in Subjects With Chronic Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to assess the tolerability, pharmacokinetics and antiviral activity
      of HEC74647 in HCV treatment naïve subjects with genotypes 1-6.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will be receive QD doses of HEC74647 or the matching placebo for 3 days to
      assess the the tolerability, pharmacokinetics and antiviral activity at specified time-points
      during the study.All subjects also will be monitored for up to 8 days post-dose to determine
      the persistence of viral mutations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Actual">January 21, 2020</completion_date>
  <primary_completion_date type="Actual">January 17, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events,laboratory abnormalities and other abnormalities</measure>
    <time_frame>8 days</time_frame>
    <description>Number of participants with Adverse Events, laboratory abnormalities and other abnormalities following dose administration of HEC74647</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral Activity</measure>
    <time_frame>8 days</time_frame>
    <description>Change from baseline in HCV RNA following dose administration of HEC74647</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sequence changes in the NS5A coding region</measure>
    <time_frame>8 days</time_frame>
    <description>Sequence changes in the NS5A coding region of HCV following multiple dose administration of HEC74647 and for up to 8 days thereafter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>8 days</time_frame>
    <description>Maximum observed plasma concentration of HEC74647</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>8 days</time_frame>
    <description>Time of the maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>8 days</time_frame>
    <description>Area under the plasma concentration-time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>8 days</time_frame>
    <description>Terminal elimination half-life</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>up to HEC74647PA capsule 50 mg once daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>up to HEC74647PA capsule 100 mg once daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>up to HEC74647PA capsule 200 mg once daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>up to placebo once daily for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC74647PA capsule</intervention_name>
    <description>Capsule administered orally once daily</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>HEC74647PA capsule matching placebo administered orally once daily</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to comprehend and sign the ICF voluntarily prior to initiate the study;

          -  Able to complete the study according to the protocol;

          -  Agree to use protocol defined precautions against pregnancy

          -  Body weight of male and female subject should be ≥50 kg and ≥45 kg respectively; Body
             Mass Index (BMI) is between 18 and 30 kg/m2, inclusive;

          -  HCV treatment-naïve adult subjects with GT1-6 HCV infection

          -  HCV RNA level ≥ 5 log10 IU/mL at screening

          -  FibroScan score within 6 months≤12.5 kPa or Liver biopsy results within 12 months
             proved Non-cirrhosis

        Exclusion Criteria:

          -  Smokers, who smoke more than 5 cigarettes/day within 3 months before the study;

          -  Drink frequently, namely alcohol consumption are 14 units per week (1 unit = 285 mL of
             beer, or 25 mL of strong wine, or 100 mL of grape wine);

          -  Donated blood or massive blood loss within 3 months before screening (&gt;450 mL）;

          -  Have any disease that increases the risk of bleeding, such as acute gastritis or
             stomach and duodenal ulcers;

          -  Have taken any prescription drug, over-the-counter drug, vitamin product or herbal
             medicine within 14 days prior to screening;

          -  Have taken any drug that inhibit gastric acid secretion, such as H2 receptor
             antagonist famotidine and proton pump inhibitor omeprazole;

          -  Have participated in any clinical trial or taken any study drug within 3 months before
             dosing;

          -  Positive test result of HBV,HIV or syphilis;

          -  Solid organ transplanters
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhua Ding, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

